echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > The two major pharmaceutical companies have reached a strategic cooperation, opening up new attempts and new opportunities for pharmaceutical cooperation models

    The two major pharmaceutical companies have reached a strategic cooperation, opening up new attempts and new opportunities for pharmaceutical cooperation models

    • Last Update: 2022-08-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    [Pharmaceutical Network Enterprise News] Recently, Kun Pharmaceutical Group Pharmaceutical Commercial Co.
    , Ltd.
    and Lunan Pharmaceutical Group officially signed an in-depth strategic cooperation agreement
    .

    The two parties will integrate their respective advantageous resources and explore multi-field and multi-dimensional cooperation models
    .

     The two major pharmaceutical companies have reached a strategic cooperation (the picture comes from the pharmaceutical network) With the in-depth implementation of the "Healthy China" strategy, the reform of the medical and health system has advanced to a deeper level, and the pharmaceutical distribution industry has entered a new era of historic changes.
    Policies and trends, it is very important to further strengthen the friendly cooperation and complementary advantages of upstream and downstream enterprises
    .

    The cooperation between Kunpharm Commercial and Lunan Pharmaceutical will also further achieve mutual benefit and mutual assistance
    .

    It is understood that Lunan Pharmaceutical is a comprehensive pharmaceutical group integrating the production, scientific research and sales of pharmaceuticals, chemicals and biological products.
    The starting point is to continuously increase investment in R&D and innovation, and strive to promote high standards and internationalization of R&D level
    .

    For example, the company established an international drug research and development center in 2017, and has completed the research and development registration of 44 preparations in 80 countries
    .

    Kunpharm Commercial has always been actively exploring the value approach in the field of pharmaceutical circulation with the core values ​​of "openness, innovation, professionalism and efficiency", and is committed to creating an ecological platform for regional pharmaceutical circulation with innovative value
    .

    It is anchored to become a comprehensive pharmaceutical service platform with grassroots advantages, pure sales ability and network value in Yunnan Province; consolidate grassroots market, deeply cultivate pharmaceutical circulation business, continuously improve business structure, and focus on grassroots network advantages; continue to promote internal strategic centralized procurement, Actively introduce domestically sourced varieties, consolidate basic management, and promote the coordinated development of subsidiaries
    .

    To improve the efficiency of logistics services, multi-warehouse weaving and network penetration, to create an integrated, standardized and intensive modern pharmaceutical logistics system, and to build an efficient, agile and intelligent modern supply chain service channel
    .

       The signing of this strategic cooperation agreement is a new starting point for symbiosis and win-win for Kunpharm Commercial and Lunan Pharmaceutical
    .

       Among them, Lunan Pharmaceutical pointed out that Lunan Pharmaceutical Group is a large national comprehensive pharmaceutical group, and the enterprise is in a high position in terms of product quality level, independent innovation ability and management level; Kun Pharmaceutical Business has a strong marketing network in Yunnan Province.
    And market innovation capabilities, the two companies use this strategic cooperation to achieve mutual benefit and mutual assistance, and strong alliances to achieve win-win cooperation
    .

       Kunpharm Group stated that the two parties have reached a consensus on this strategic cooperation based on the goal of complementary advantages and win-win development
    .

    Kunpharm Commercial will firmly consolidate the basic management, accelerate the three-year strategic goal of pure sales transformation, firmly establish the value chosen by upstream industrial enterprises, share resources with Lunan Pharmaceutical, and achieve a new leap in cooperation
    .

       Kunpharm Group also stated that Kunpharm Commercial will go all out to give full play to its grassroots advantages, cooperate with Lunan Pharmaceutical to promote strategic varieties, solidify the stock market foundation, and help Lunan Pharmaceutical to deploy more efficient business channels
    .

    Kunpharm Commercial will also rely on this cooperation to realize business empowerment and strategic upgrade
    .

       Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
    .

     
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.